Literature DB >> 1391672

Assessing Alzheimer severity with a global clinical scale.

J W Ashford1, V Kumar, M Barringer, M Becker, J Bice, N Ryan, S Vicari.   

Abstract

Diagnosis of dementia needs to be complemented by precise determination of disease severity across the broad spectrum of disease progression. The Mini-Mental State Exam (MMS), the Activities-of-Daily-Living assessment (ADL) and the Clinical Dementia Rating scale (CDR) were modified for direct comparability and administered to 112 outpatients and 45 nursing home residents with a range of dementia severity from mild to profound. The scales showed the highest correlations for the probable Alzheimer's disease patient group (62) (Global Assessment of Dementia; GAD vs. ADL: r = 0.91; Extended Mini-Mental Assessment; EMA vs. GAD: r = 0.91; ADL vs. EMA: r = 0.86). For these patients, scores on the individual scales tended to be similar. Disparity among the three scores for individual cases was associated with the presence of comorbidities. The high correlations and correspondence among these scales demonstrate their reliability, validity, and utility in the assessment of dementia severity. The use of an average of these measures, with their increased precision, may give a more accurate indication of dementia severity over a broader range of impairment.

Entities:  

Mesh:

Year:  1992        PMID: 1391672     DOI: 10.1017/s1041610292000905

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  9 in total

1.  Biomarkers of basic activities of daily living in Alzheimer's disease.

Authors:  James R Hall; Leigh A Johnson; Robert C Barber; Hoa T Vo; A Scott Winter; Sid E O'Bryant
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Cerebral metabolic correlates of four dementia scales in Alzheimer's disease.

Authors:  E Salmon; S Lespagnard; P Marique; F Peeters; K Herholz; D Perani; V Holthoff; E Kalbe; D Anchisi; S Adam; F Collette; G Garraux
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

3.  MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia.

Authors:  J W Ashford; M Adamson; T Beale; D La; B Hernandez; A Noda; A Rosen; R O'Hara; J K Fairchild; D Spielman; J A Yesavage
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 4.  Modeling the time-course of Alzheimer dementia.

Authors:  J W Ashford; F A Schmitt
Journal:  Curr Psychiatry Rep       Date:  2001-02       Impact factor: 5.285

5.  Validity and reliability of the persian version of lawton instrumental activities of daily living scale in patients with dementia.

Authors:  Afsoon Hassani Mehraban; Yasamin Soltanmohamadi; Malahat Akbarfahimi; Ghorban Taghizadeh
Journal:  Med J Islam Repub Iran       Date:  2014-05-03

Review 6.  The Dichotomy of Alzheimer's Disease Pathology: Amyloid-β and Tau.

Authors:  J Wesson Ashford
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

7.  A Computerized Continuous-Recognition Task for Measurement of Episodic Memory.

Authors:  J Wesson Ashford; Franck Tarpin-Bernard; Curtis B Ashford; Miriam T Ashford
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

8.  Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer's disease.

Authors:  Steven Douglas Maynard; Jeff Gelblum
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-23       Impact factor: 2.570

Review 9.  microRNA-Based Biomarkers in Alzheimer's Disease (AD).

Authors:  Yuhai Zhao; Vivian Jaber; Peter N Alexandrov; Andrea Vergallo; Simone Lista; Harald Hampel; Walter J Lukiw
Journal:  Front Neurosci       Date:  2020-10-30       Impact factor: 4.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.